Novus Biologicals Announces New Beta Amyloid Pyroglutamate Antibodies

Novus Biologicals, a leading international supplier of high quality antibodies and proteins to the bioresearch industry, is pleased to announce the introduction of a new range of Beta Amyloid antibodies to their antibody catalog.  Playing a pivotal role in Alzheimer's Disease research, of particular interest are two pyroglutamate forms targeted to different N-terminal E-start points.

As well as the Abeta antibody (NBP1-44047), the new antibodies Novus just released include Beta Amyloid [pyroglutamate3] antibody (NBP1-44048), and Beta Amyloid [pyroglutamate11] Antibody (NBP1-44070), which are targeted at the N-terminus 3-pyro and N-terminus 11-pyro E start points, respectively.  Novus also supplies the related blocking peptides (NBP1-44964, NBP1-44969 and NBP1-44975).

Alzheimer's disease is characterized by the formation of cerebral and vascular plaques.  These are caused by an excess build-up of beta Amyloid (Abeta) peptides in the brain, something that was first noted in 1991.  Recently, it was reported that N-truncated peptides undergoing pyroglutamic acid synthesis at positions 3 and 11 - predominantly 3 - are a major componenet of plaque formation in Alzheimer's patients.  These modified peptides are more hydrophobic, more resistant to degradation, more prone to aggegation and - in some cases - more toxic than the non-truncated form.  Studies are therefore now focused on the molecular pathways leading to the formation of truncated beta Amyloid 3 and 11 peptides, for which the three new antibodies released by Novus will prove invaluable.  Scientists are hopeful this will eventually lead to the development of immunotherapies effective against Alzheimer's Disease.  Vaccines so far developed mainly target the N-terminal epitope of the full-length protein; this epitope is absent from the truncated forms.

Dr. Mark Parker, senior scientist and head of product development for Novus, explains: "The association between beta amyloid proteins and Alzheimer's has been known since the 1990's, but it is only since the discovery of these N-truncated forms that real advancements have been made.  Our new Abeta and beta Amyloid pyroglutamate antibodies target all three major proteins currently being studied by Alzheimer's Disease researchers, and come with a 100% guarantee of quality and effectiveness."



For more information on these new Beta Amyloid Pyroglutamate antibodies or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Thursday, August 26, 2010 - 06:00